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a B s t r aC t
gout is an acute inflammatory arthritis with the potency 
to fully destroy the integrity of the joint leading to 
severe disability. Besides joint destruction, gout is often 
associated with an accelerated atherosclerosis culminating 
in an increased risk of cardiovascular disease. the current 
existing therapy modalities allow an efficient treatment 
that not only controls local inflammation but might also 
have an effect on the generalised features that surround 
this condition. here we discuss the modes of clinical 
appearance, how we are nowadays supposed to treat gout 
and the current knowledge about the pathogenesis of this 
clinical syndrome. 
K e Y wor ds
Gout, cardiovascular risk, immunology
i n t roduC t i on
Gout is an acute inflammatory arthritis caused by 
the deposition of monosodium urate (MSU) crystals 
intra-articularly. Patients experience acute severe pain 
that often forces them to seek medical care. Besides the 
acute presentation patients can present with tophi, which 
can even precede joint involvement.1-3 With an estimated 
prevalence of 1 to 2% in adults in developed countries, this 
therefore accounts for a substantial burden of work-related 
and medical costs. In the elderly (age >65 years) the 
incidence even increases to 8% for men and 3% for 
women.4 The male:female ratio ranges from 7:1 to 9:1.5 
Most patients with gout (±90%) are diagnosed and treated 
by general practitioners in primary care.6 
Besides the involvement of joints, gout is often accompanied 
by other symptoms of hyperuricaemia such as the 
formation of tophi in numerous tissues. The prevalence of 
hyperuricaemia is 10 to 20% in the Western population and 
a substantial number of these patients stay asymptomatic 
during life.7 Only a minority of individuals with elevated 
serum urate levels develop gout (incidence rate less than 
50/1000/year for ≥0.54 mmol/l; 5/1000/year for 0.42 to 
0.54 mmol/l; 1/1000/year <0.42mmol/l).8 Compared with 
other mammals humans have high uric acid levels due to 
two deletions in the promotor site of uricase.9 This causes 
the uric acid plasma levels to be around 300 mM, a level 
at which a small increment could cause supersaturation 
and crystal formation. There is a strong association 
between hyperuricaemia and the metabolic syndrome (the 
constellation of insulin resistance, hypertension, obesity 
and dyslipidaemia), potentially explained by dietary and 
lifestyle changes.10 This is profoundly demonstrated by 
the prototypic gouty patient being an obese, middle-aged 
man with a Burgundian lifestyle and a medical history of 
hypertension, kidney disease, diabetes mellitus and signs 
of vascular problems such as coronary artery disease, 
heart failure and stroke. But as previously reported gout 
can also present in elderly patients without known risk 
factors, even presenting only with tophi.11 In gouty arthritis 
the formation of MSU crystals into the joint promotes 
acute inflammation. These crystals have the capacity to 
induce the release of various inflammatory mediators in 
inflammatory cells.12-16 In the past ten years research on 
the role of the innate immune system in the pathogenesis 
of gout has extended rapidly. As our knowledge on the 
inflammatory processes accompanying atherosclerosis 
also increases it is tempting to discuss the development of 
cardiovascular diseases in gout patients via immunological 
perturbations. 
In daily clinical practice the diagnosis of gout can be made 
easily and with a high certainty using the gold standard. 
The gold standard is the presence of MSU crystals in the 
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synovial fluid or a tophus, and therefore a puncture of a 
joint or tophus should always be performed. Recently it 
was shown that the American College of Rheumatology 
(ACR) criteria from 1977 have a limited validity, at least in 
primary care.17 We describe two patients who visited the 
emergency department because of severe gouty arthritis. 
The aim of this study is to review the literature concerning 
cardiovascular risks and pathogenic aspects of gout. In 
addition, we provide an overview on the clinical assessment 
and therapeutic armamentarium.
C a se s
Pat i e n t  a
A 75-year-old male presented at the emergency unit with 
a five-day history of severe pain and swelling of digit 
IV of the left foot. The general practitioner had already 
started colchicine 0.5 mg ten times daily. This led to 
complaints of vomiting and diarrhoea and eventually to 
a visit to the emergency department. His medical history 
was characterised by major cardiovascular complications 
consisting of a myocardial infarction in 1986 followed by a 
large aneurysm of the left ventricle and mild mitral valve 
insufficiency (diagnosed in 1993). A second myocardial 
infarction followed in 1994. In 2002 an acute coronary 
syndrome led to dilation  and placement of a stent in the 
right coronary artery. In 2008 diagnostic procedures were 
undertaken because of progressive dyspnoea and cardiac 
ultrasound revealed a markedly diminished function of the 
left ventricle (ejection fraction 25 to 30%), insufficiency of 
the mitral and aortal valves and suspicion of pulmonary 
arterial hypertension. Based on these observations, an 
intracardiac defibrillator was inserted. Besides his cardiac 
history, hypothyroidism, peptic ulcers and gout had been 
present for eight years. Physical examination revealed 
a swelling of digit IV of his left foot with a tophus 
that showed signs of infection and distinct tophi in the 
olecranal bursa bilaterally (figures 1A and B). Apart from 
the common signs of dehydration, no other signs of illness 
were present. Laboratory analysis was normal (no acute 
phase response present) except for the increased serum 
uric acid of 0.92 mmol/l (reference 0.20 to 0.40 mmol/l) 
and creatinine 306 mmol/l (reference 60 to 110 mmol/l) 
levels. Radiographic evaluation of the left foot revealed 
a complete resorption of the distal phalanx digit IV 
(figure 1C); no other abnormalities were present. Since the 
patient was dehydrated because of diarrhoea due to the 
high dose of colchicine, 120 mg, the arthritis was treated 
with triamcinolone acetonide intramuscularly and not 
with an NSAID, and the dosage of colchicine was lowered 
to 0.5 mg once daily. One week later the patient attended 
our outpatient clinic. He was fully recovered and showed 
no signs of dehydration and pain in the toe. Although 
exceptional, since the gouty disease in this patient was very 
local and led to a high risk for an infectious complication, 
we discussed an amputation of digit IV with the patient. 
Not surprisingly, the toe had given many complaints over 
the past three years and the patient agreed to this approach. 
Two weeks after presentation at the emergency ward the 
toe was amputated. As expected, the histological analysis 
of the amputated digit showed clear MSU crystals and no 
evidence for infection. Two weeks after surgery the patient 
visited our outpatient clinic with complete healing of the 
site of amputation (figure 1D). Since the medical history 
of the patient included more than three gout attacks per 
year we started allopurinol 200 mg once daily under the 
cover of corticosteroids. This led to the normalisation of 
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figure 1. Patient A
a) digit iv of the left foot with an ulcerating wound with a tophus 
present proximally, B) lateral and frontal view of the left olecranal 
bursa with multiple subcutaneous nodules (tophi) present. C) X-ray of 
the left foot showing complete disappearance of the bone due to the 
gouty inflammation and d) left foot after amputation of digit iv. the 
patient provided consent to publish the photos.
a
d
B
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the serum urate below the level of 0.36 mmol/l, which is 
the current target value of the European League against 
Rheumatism (EULAR), and absence of gout attacks after 
two years of follow-up.
Pat i e n t  B
A 93-year-old female came to the rheumatology clinic with 
pain and swelling in both hands and a probable 12-year 
history of gout. She had not received any treatment for 
her gout so far. Her only relevant medical history was 
primary hypertension. Physical examination showed 
multiple swollen proximal interphalangeal (PIP) and 
distal interphalangeal (DIP) joints in both hands with an 
extensive amount of tophi (figures 2A and B). Inspection 
of digit IV of the right hand revealed a fistulating tophus 
(figure 2C). Laboratory analysis showed a serum uric 
acid of 0.46 mmol/l (reference 0.20 to 0.40 mmol/l) 
and creatinine 69 mmol/l (reference 60 to 110 mmol/l) 
and an acute phase reaction: ESR 34 mm/h and 
CRP 45 mg/l. To analyse the extent of joint damage 
conventional radiological examination was performed 
which revealed extensive destruction of multiple PIP and 
DIP joints (known as ‘punched out’ lesions). As treatment, 
clindamycin 200 mg was given three times daily (for two 
weeks) and methylprednisolone (120 mg) was administered 
once intramuscularly. Two weeks later all the signs of 
inflammation had completely resolved. At that moment 
allopurinol 200 mg once daily was added, which led to 
the normalisation of the serum urate level (<0.36 mmol/l). 
After two years of follow-up, the patient had twice suffered 
from a gout attack which quickly recovered (within two 
days) by the addition of colchicine three times daily 0.5 mg 
for one week. 
gou t  a n d  C a r d iova sCu l a r 
Mor B i d i t Y  a n d  Mor ta l i t Y :  Mor e 
t h a n  a  l o C a l  d i s e a s e ?
While an association between gout and hypertension, 
other cardiovascular diseases and kidney diseases has 
been observed since the late 19th century, renewed interest 
started from the late 20th century through defining 
of new top priorities in medicine, such as reduction of 
cardiovascular morbidity and mortality.1 To date, several 
studies underscore that gout is an independent risk factor 
for cardiovascular disease (table 1).10,18 
In the prospective Framingham study ‘clinical’ gout was 
associated with an increased risk of coronary heart disease. 
Abbott et al. found an excess risk of 60% for coronary heart 
disease (CHD) among subjects with gout compared with 
those who did not have clinical gout.19 The Meharry-Hopkins 
study showed contradictory results, the pooled risk-adjusted 
relative risk (RR) for cardiovascular disease was 0.59 (95% 
CI 0.24 to 1.46). However, this study was underpowered 
with just three events in the 31 subjects of the Meharry 
cohort and four events in 62 subjects of Johns Hopkins 
Precursors cohort.20 A Dutch study based on data from 
general practitioners demonstrated that 270 patients with 
a first episode of gout had a statistically higher prevalence 
of one or more signs of cardiovascular disease (35 vs 26%) 
compared with 522 healthy counterparts. In follow-up 
of this study, 170 gout patients without cardiovascular 
disease were compared with 340 control patients from the 
general practitioners’ database. Data revealed a statistically 
higher prevalence of hypertension (39 vs 14%), hypercholes-
terolaemia (8 vs 4%), diabetes mellitus (5 vs 1%) and obesity 
(52 vs 27%) among the 170 gout patients.21 
The prospective Multiple Risk Factor Intervention Trial 
(MRFIT) was a randomised clinical trial designed to 
examine the efficacy of coronary risk reduction of adverse 
coronary events. During the six-year intervention phase 
gout was associated with an increased risk of nonfatal 
acute myocardial infarction, odds ratio 1.26 (95% CI 1.14 
to 1.4).21,22 In 2008, Krishnan et al. reported a 17-year 
follow-up study of the men in the MRFIT cohort who did 
not have CHD during the six-year intervention phase. The 
hazard ratio (HR) for CHD mortality for gout vs non-gout 
was 1.35 (95% CI 1.06 to 1.72).23
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figure 2. Patient B
a to C) diffuse swelling of distal and proximal interphalangeal joints 
with multiple subcutaneous tophi and ulceration lateral side digit iv 
left, d) bone resorption and bone cysts due to chronic gouty inflamma-
tion. the patient provided consent to publish the photos.
a B
C
d
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Recently, a large Taiwanese study reported about the 
relationship between clinical gout and electrocardio graphic 
evidence Q-wave myocardial infarction using the 
Ho-Ping Gout database of 22,572 established gout 
patients according to the Wallace criteria.24 In addition 
to this, Chen et al. demonstrated that gout was associated 
with Q-wave myocardial infarction.25 The prospective 
Health Professional Follow-up Study investigated the 
relation between history of gout and the risk of death 
and myocardial infarction among 51,297 men. During 
the 12-year follow-up period, Choi et al. found RRs of 
1.38 (95% CI 1.15 to 1.66) for cardiovascular-related death 
and 1.55 (95% CI 1.24 to 1.93) for cardiovascular-related 
death in males with gout.26 Cohen et al. examined the 
association of gout and mortality among patients receiving 
dialysis therapy in the United States Renal Data System. 
In this study, gout was independently associated with 
CVD mortality with an HR of 1.47 (95% CI 1.26 to 1.59).27 
However, this national registry did not contain information 
on other potential risk factors for mortality such as 
malnutrition, infection and social circumstances. The 
most recent study to date by Kuo et al. further substantiates 
the relationship between cardiovascular disease and gout 
using a cohort of 61,527 individuals and a follow-up period 
of seven years.28 
Together, these prospective reports strongly suggest that 
men with gout, adjusted for various cardiovascular risk 
factors, are associated with increased cardiovascular 
disease risk, especially coronary heart disease mortality. 
Therefore aggressive management of cardiovascular risk 
factors in men with gout is warranted. 
gou t  a n d  P e r t u r B at i ons  i n  t h e 
i MMun e  s Y s t eM 
Whenever the level of uric acid in the synovial fluid 
fluctuates and the synovial fluid gets supersaturated 
with uric acid the risk for crystal formation increases. 
The solubility of urate in synovial fluid is influenced by 
more factors than solely the concentration, including 
temperature, level of dehydration and the presence of 
nucleating agents.29 These factors in part explain the 
predilection of gout in the first metatarsal phalangeal 
joint (podogra, low temperature), in osteoarthritic joints 
(nucleating debris) and the nocturnal onset (dehydration).29 
An acute gouty attack causes a neutrophilic influx. 
The influx of neutrophils into the joint is caused by 
chemotactic factors.30 Recent studies have shown that the 
most important phagocytic cells causing this gradient 
are the monocytes. Interaction between MSU and the 
lipid membrane and proteins in the cell membrane of a 
phagocyte cause activation of several signal transduction 
pathways resulting in IL-8 production, accounting for 
90% of the neutrophilic chemotactic activity.30 Other 
neutrophilic chemoattractant factors include S100A8 
and S100A9.31 MSU released by injured cells act as a 
danger signal activating the innate immune system.32 
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table 1. Gout and cardiovascular morbidity and mortality
study Population design follow-up 
(years)
outcomes Patients (total 
gout n)
adjusted effect 
size (95% Ci)
Abbott19 Framingham cohort Cohort 32 CHD 37 (94) 1.60 (1.10-2.50)
Gelber20 Meharry-Hopkins 
cohort
Cohort 30 CHD 7 (93) 0.59 (0.24-1.46)
Janssens21 Continuous Morbidity 
Registration cohort
Case-control 11 CVD 44 (170) (0.65-1.47)
Krishnan22 Multiple risk factor 
Intervention trial 
Cohort
Cohort 6.5 Fatal MIs
All MIs
22 (1123)
118 (1123)
0.96 (0.66-1.44)
1.26 (1.14-1.40)
Krishnan23 Multiple risk factor 
Intervention trial 
Cohort
Cohort 17 Fatal MIs
CHD mortality
CVD mortality
36 (655)
78 (655)
110 (655)
1.35(0.94-1.93)
1.35(1.06-1.72)
1.21 (0.99-1.49)
Chen25 Ho-Ping Gout Cohort Cross-sectional NA Q-wave MIs 393 (22,572) 1.18 (1.01-1.38)
Choi26 Health Professionals
Follow-up cohort
Cohort 12 All-cause 
mortaility
CHD mortality
CVD mortality
645 (2773)
238 (2773)
304 (2773)
1.28 (1.15-1.41)
1.55 (1.24-1.93)
1.38 1.15-1.66)
Cohen27 US Renal Data System 
dialysis patients
Cohort 5 All-cause 
mortality 
CVD mortality
*(24,415)
*(24,415)
1.49 (1.43-1.55)
1.47 (1.26-1.59)
Kuo28 Health Screening 
Program Chang Gung 
Memorial Hospital
Cohort 6 All-cause 
mortality
CVD mortality
*(1311)
*(1311)
1.46 (1.12-1.91)
1.97 (1.08-3.59)
*numbers of outcome not reported.
Chd = coronary heart disease; Cvd = cardiovascular disease; Mis = myocardial infarctions.
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MSU crystals are potentially recognised by immune cells 
through Toll-like receptor 2 (and probably TLR4)33,34 and 
FcγRIIIB/CD1635 subsequently leading to NF-kappaB 
activation and downstream signalling culminating in 
the production of proinflammatory cytokines such as 
interleukin-6, tumour necrosis factor α, interleukin-1β 
and interleukin-8 (IL-8). Actually, the stimulating capacity 
of MSU crystals to activate monocytes/macrophages to 
produce interleukin-1β (IL-1β) was already recognised 
20 years ago but to date controversy remains about the 
precise mechanisms through which urate crystals drive 
inflammation.12 Recent studies have led to significant 
advances in the understanding of the basic biology of 
crystal-mediated inflammation. Uric acid has been 
identified as a danger signal that triggers a cytosolic 
sensor, the inflammasome, a signalling platform that 
is required for the activation of interleukin-1, a cytokine 
that is critical to the initiation of acute inflammation 
in gout (reviewed in Martinon, 2010).36 Interestingly, 
several studies have now suggested an effective treatment 
with IL1b inhibitors; however, these observations 
need confirmation in RCTs.37,38 Currently a study with 
canakinumab, an IL1b inhibitor, is underway. Another 
interesting finding recently published is the capacity of 
monocytes and/or the inflammatory environment in a 
gout-prone individual to prime neutrophils to produce 
increased levels of superoxide in response to MSU 
stimulation.39 
Intriguingly, the natural course of a gout attack is to 
spontaneously resolve in seven to ten days. Clearance 
of MSU by differentiated macrophages results in a 
decrease of leucocyte and endothelial activation with the 
end result that the inflammatory response fades away.40 
Further in vitro research showed that in vitro generated 
macrophages failed to secrete cytokines in response to 
MSU.40 It is therefore interesting to hypothesise that the 
time to resolve a gout attack is directly correlated with the 
time a monocyte needs to become a fully differentiated 
macrophage in vitro. Further research is needed though 
to confirm this hypothesis. On the other hand in chronic 
gout low-grade synovitis persists even during remissions 
of acute flares. The ongoing inflammation causes joint 
damage through chondrocyte activation and the following 
matrix metalloproteinase production.41 Furthermore, MSU 
is able to reduce the anabolic effects of osteoblasts, also 
contributing to irreversible joint damage. These series of 
events could possibly explain the inflammatory circuitry 
that leads to joint destruction when inflammation is not 
controlled (figure 3). Next to irreversible joint damage 
the increased cardiovascular risk in patients with gout is 
Bhansing, et al. Gout.
figure 3. Schematic overview of the pathogenesis of gout
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still a medical conundrum. Two interesting hypotheses 
try to explain the pathophysiological mechanisms that 
lead to the accelerated atherosclerosis that underlies this 
phenomenon. First, activation of Toll-like receptors (TLRs) 
can block the induction of liver X receptor (LXR) target 
genes of the lipid metabolism.42 As activation of LXR and 
PPAR gamma can potentially prevent the development 
of atherosclerosis, an interaction between LXR and MSU 
induced TLR activation could explain the association with 
the uncontrolled rate of atherosclerosis in patients with 
gout. Second, two studies in rats, using dietary adjustments 
to induce hyperuricaemia, have shown that increased uric 
acid caused nephropathy resulting in increased renin levels 
and hypertension.43,44 Whether this mechanism can be 
translated to humans is a matter of debate and warrants 
further investigation. In addition, the contribution of 
chronic inflammation, oxidative stress and endothelial 
dysfunction to the development of cardiovascular disease 
in gout patients needs further attention as these processes 
intriguingly play a role in both diseases. 
Cu r r en t  i n s i gh t s  i n t o  t h e 
M a nageM en t  o f  g ou t
Following the clear evidence of the destructive effects of gout 
on the joints and the cardiovascular system a clinician facing 
a patient with gout should be triggered to start treatment for 
these aspects of this disease. The EULAR evidence-based 
recommendations for gout is a European combined effort 
to develop key recommendations concerning diagnosis and 
management of gout.4,45 A total of 22 key recommendations 
were generated through six Delphi rounds. Table 2 presents 
a selection of the most important key recommendations 
for management of gout. In the short term, the treatment 
goal is to relieve symptoms as quickly as possible. For this 
purpose oral colchicine (dose needs to be corrected for 
renal function), NSAIDS or a low dose of oral prednisone 
can be used. The importance of using the correct dosage of 
colchicine is clearly illustrated in patient A who was nearly 
intoxicated. The efficacy of colchicine and its side effect is 
further discussed in Terkeltaub et al.46 In a double-blinded 
randomised clinical trial oral prednisone and naproxen were 
found to be equally effective in the initial treatment of gout 
arthritis over four days.47 In the longer term, urate-lowering 
therapy is indicated in patients with recurrent acute gout 
attacks, arthropathy, tophi or radiographic changes of gout. 
The first choice for urate-lowering therapy is a xanthine 
oxidase inhibitor (allopurinol). Allopurinol has a proven 
efficacy in all cases of gout. The most common dosage of 
allopurinol is 300 mg once-daily with which 56 to 65% 
of patients reach the recommended urate level of <0.36 
mmol/l.48,49 If necessary, this dose can be increased to 600 
mg daily. In 20% of the cases the use of allopurinol causes 
side effects which are severe enough to stop treatment in 
5% of the cases.50 If there is intolerance against allopurinol 
an alternative approach is the use of an uricosuric drug; in 
the Netherlands benzbromarone as the only drug regularly 
available. In a recent randomised controlled trial the efficacy 
of benzbromarone 100 to 200 mg daily was equal to 300 
to 600 mg allopurinol.51 Recently, a novel drug for the 
treatment of gout was introduced: febuxostat (Adenuric®). 
Feboxostat is a novel non-purine xanthine oxidase inhibitor. 
Urate levels of lower than 0.36 mmol/l were reached in 48 
to 53% with daily use of 80 mg febuxostat and in 62 to 65% 
in the case of 120 mg febuxostat daily vs 56 to 62% and 85 
to 93% with the use of 300 mg and 600 mg of allopurinol 
daily.52-54 However, the current position of febuxostat in the 
Netherlands is as a second choice after failure of allopurinol 
and/or benzbromarone (See Dutch Guidelines febuxostat 
www.nvr.nl) following the international recommendations.55 
Currently, there is a large debate about the effects that these 
treatments could have on cardiovascular risk. Aside from this 
urate-lowering therapy traditional cardiovascular risk factors 
such as hyperlipidaemia, hypertension, obesity and smoking 
should be addressed according to national cardiovascular risk 
management guidelines. Although clear trends are present 
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table 2. Modified recommendations for management 
of gout45 
1. Optimal treatment of gout requires both nonpharmaco-
logical and pharmacological modalities and should be 
tailored according to:
(a) Specific risk factors for gout such as elevated serum uric 
acid, previous attacks and radiographic signs
(b) Clinical phase (acute/recurrent, chronic tophaceous gout)
(c) General risk factors (age, sex, obesity, alcohol consump-
tion, urate raising drugs, drug interactions and comorbidity)
2. NSAID and/or prednisolone are first-line agents for 
systemic treatment of acute attacks. Low-dose colchicine is 
an alternative.
3. Intra-articular aspiration and injection of a long-acting 
steroid is an effective and safe treatment for an acute attack.
4. Urate-lowering therapy is indicated in patients with 
recurrent acute attacks, arthropathy, tophi or radiographic 
changes of gout. The therapeutic goal of urate-lowering 
therapy is achieved by maintaining the serum uric below 
the saturation point of monosodium urate (< 360mmol).
5. Allopurinol is an appropriate long-term urate-lowering 
drug; it should be started at a low dose (for example, 100 mg 
daily) and increased by 100 mg every 2-4 weeks if required; 
the dose must be adjusted in patients with renal impair-
ment; if allopurinol toxicity occurs, options include other 
xanthine oxidase inhibitors, an uricosuric agent (benzbro-
marone) or allopurinol desensitisation (the latter only in 
cases of mild rash).
6. Prophylaxis against acute attacks during the first months 
of urate-lowering therapy can be achieved by colchicine 
(0.5-1 mg daily) and/or an NSAID.
7. When gout is associated with diuretic therapy, stop the 
diuretic if possible: for hypertension and hyperlipidaemia 
consider use of losartan and fenofibrate, respectively(both 
have modest uricosuric effects).
8. Associated comorbidity and cardiovascular risk factors such 
as hyperlipidaemia, hypertension, hyperglycaemia, obesity 
and smoking should be addressed as an important part of 
the management of gout.
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that suggest that gout/hyperuricaemia is associated with an 
increased risk for premature death due to cardiovascular 
diseases, the final answer needs to come from clinical 
intervention studies that still need to be performed. 
ConC lus i on
The cases discussed in this report clearly illustrate the 
severity of gout and demonstrate that even today, gout 
is not always recognised and treated as it should be. 
Nowadays, gout can be treated very effectively with the 
currently available therapeutic armamentarium. So 
far, prospective studies supported by evidence from 
basal immunology studies clearly show that gout is an 
independent risk factor for CVD. In the coming years the 
precise interplay of inflammatory mediators mediating the 
arthritic symptoms and the potential connection with an 
increased cardiovascular disease profile is to be expected. 
For now, correct and proactive management of gout taking 
into account the present risk factors for the development of 
cardiovascular disease should have a place in the treatment 
of every patient with this clinical syndrome.
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